These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 26810718)

  • 21. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
    Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
    Front Immunol; 2022; 13():873576. PubMed ID: 35432315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
    Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: A retrospective cohort study.
    Luo W; Shi Z; Kong L; Wang X; Zhou H
    Eur J Neurol; 2024 Mar; 31(3):e16178. PubMed ID: 38117536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder.
    Seok JM; Cho EB; Lee HL; Cho HJ; Min JH; Lee KH; Kim BJ
    J Neurol Sci; 2016 Sep; 368():209-13. PubMed ID: 27538635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low T3 syndrome in neuromyelitis optica spectrum disorder: Associations with disease activity and disability.
    Cho EB; Min JH; Cho HJ; Seok JM; Lee HL; Shin HY; Lee KH; Kim BJ
    J Neurol Sci; 2016 Nov; 370():214-218. PubMed ID: 27772762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
    Ringelstein M; Ayzenberg I; Harmel J; Lauenstein AS; Lensch E; Stögbauer F; Hellwig K; Ellrichmann G; Stettner M; Chan A; Hartung HP; Kieseier B; Gold R; Aktas O; Kleiter I
    JAMA Neurol; 2015 Jul; 72(7):756-63. PubMed ID: 25985228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patients.
    Uzawa A; Mori M; Masuda H; Uchida T; Muto M; Ohtani R; Aoyama S; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2024 Jun; 95(7):626-629. PubMed ID: 38176896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder.
    Shimizu Y; Fujihara K; Ohashi T; Nakashima I; Yokoyama K; Ikeguch R; Takahashi T; Misu T; Shimizu S; Aoki M; Kitagawa K
    Mult Scler; 2016 Oct; 22(11):1413-1420. PubMed ID: 25921053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
    Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
    Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
    Jacob A; Matiello M; Weinshenker BG; Wingerchuk DM; Lucchinetti C; Shuster E; Carter J; Keegan BM; Kantarci OH; Pittock SJ
    Arch Neurol; 2009 Sep; 66(9):1128-33. PubMed ID: 19752302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe Relapse After Cessation of Immunosuppressive Therapy in a Patient With Neuromyelitis Optica Spectrum Disorder.
    Hyun JW; Kim G; Kim Y; Jeong IH; Kim SH; Kim HJ
    Neurologist; 2016 Nov; 21(6):97-98. PubMed ID: 27801768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
    Elsone L; Kitley J; Luppe S; Lythgoe D; Mutch K; Jacob S; Brown R; Moss K; McNeillis B; Goh YY; Leite MI; Robertson N; Palace J; Jacob A
    Mult Scler; 2014 Oct; 20(11):1533-40. PubMed ID: 24647557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.